DK1227840T3 - Adjuverede, genetiske vacciner - Google Patents

Adjuverede, genetiske vacciner

Info

Publication number
DK1227840T3
DK1227840T3 DK99956885T DK99956885T DK1227840T3 DK 1227840 T3 DK1227840 T3 DK 1227840T3 DK 99956885 T DK99956885 T DK 99956885T DK 99956885 T DK99956885 T DK 99956885T DK 1227840 T3 DK1227840 T3 DK 1227840T3
Authority
DK
Denmark
Prior art keywords
genetic vaccines
adjuvanted
adjuvanted genetic
inducing
nucleic acid
Prior art date
Application number
DK99956885T
Other languages
Danish (da)
English (en)
Inventor
Joel R Haynes
James T Fuller
Deborah Fuller
Georg Widera
Timothy Shipley
Mary Wu
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Application granted granted Critical
Publication of DK1227840T3 publication Critical patent/DK1227840T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
DK99956885T 1999-11-03 1999-11-03 Adjuverede, genetiske vacciner DK1227840T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/025854 WO2001032208A1 (en) 1999-11-03 1999-11-03 Adjuvanted genetic vaccines

Publications (1)

Publication Number Publication Date
DK1227840T3 true DK1227840T3 (da) 2008-02-04

Family

ID=22273970

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99956885T DK1227840T3 (da) 1999-11-03 1999-11-03 Adjuverede, genetiske vacciner

Country Status (14)

Country Link
EP (1) EP1227840B1 (https=)
JP (1) JP2003516936A (https=)
CN (1) CN100333794C (https=)
AT (1) ATE374622T1 (https=)
AU (1) AU780448C (https=)
CA (1) CA2389686A1 (https=)
CY (1) CY1107845T1 (https=)
DE (1) DE69937258T2 (https=)
DK (1) DK1227840T3 (https=)
ES (2) ES2340617T3 (https=)
IL (2) IL149415A0 (https=)
NZ (1) NZ518766A (https=)
PT (2) PT1913957E (https=)
WO (1) WO2001032208A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1227840T1 (sl) * 1999-11-03 2008-02-29 Powderject Vaccines Inc Genetske vakcine z adjuvansom
JP2004535799A (ja) * 2001-05-18 2004-12-02 パウダージェクト ワクチンズ，インコーポレーテッド ワクチン組成物
US7566478B2 (en) 2001-07-25 2009-07-28 Nantero, Inc. Methods of making carbon nanotube films, layers, fabrics, ribbons, elements and articles
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
WO2014145906A2 (en) * 2013-03-15 2014-09-18 Phd Preventative Health Care And Diagnostics, Inc. A prefilled medication device, method of making and using the same
US11771761B2 (en) 2019-06-12 2023-10-03 Wisconsin Alumni Research Foundation Adjuvant for animal and human vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE303160T1 (de) * 1993-08-11 2005-09-15 Jenner Technologies Impfstoff gegen prostatakrebs
CA2158733C (en) * 1994-01-21 2007-01-16 Dennis E. Mccabe Gas driven gene delivery instrument
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
DE69738597T2 (de) * 1996-02-09 2008-07-24 Glaxosmithkline Biologicals S.A. Vakzine gegen das varicella zostervirus produkt von gen 63
EP1017283B1 (en) * 1997-02-14 2004-12-15 Merck & Co., Inc. Polynucleotide vaccine formulations
WO1998046263A1 (en) * 1997-04-14 1998-10-22 University Of Massachusetts Medical Center Saponin adjuvants in combination with dna vaccination
NZ504894A (en) * 1997-12-02 2002-12-20 Powderject Vaccines Inc Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique
GB9818627D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
CU22740A1 (es) * 1998-09-07 2002-02-28 Ct Ingenieria Genetica Biotech Formulación de ácidos nucleicos y acemanano

Also Published As

Publication number Publication date
CN1426309A (zh) 2003-06-25
PT1227840E (pt) 2008-01-09
PT1913957E (pt) 2010-05-05
DE69937258D1 (de) 2007-11-15
ATE374622T1 (de) 2007-10-15
CA2389686A1 (en) 2001-05-10
CN100333794C (zh) 2007-08-29
CY1107845T1 (el) 2013-06-19
AU1339900A (en) 2001-05-14
EP1227840B1 (en) 2007-10-03
ES2340617T3 (es) 2010-06-07
AU780448C (en) 2006-02-23
IL149415A (en) 2008-11-03
ES2294864T3 (es) 2008-04-01
DE69937258T2 (de) 2008-07-03
JP2003516936A (ja) 2003-05-20
AU780448B2 (en) 2005-03-24
EP1227840A1 (en) 2002-08-07
IL149415A0 (en) 2002-11-10
WO2001032208A1 (en) 2001-05-10
NZ518766A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
DE69929444D1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
NZ540544A (en) Nucleic acids and proteins from streptococcus groups A & B
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
CY1107390T1 (el) Εμβολιο εναντι αντιγονων απο βακτηριδια
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
DE60037900D1 (de) Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
CY1107845T1 (el) Γενετικα εμβολια με ανοσοενισχυτικο
WO2004098526A3 (en) Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
SE9903534D0 (sv) Vaccin
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
ATE460945T1 (de) Genetische adjuvanz-impfstoffe
DK1490100T3 (da) Kombinerede DNA/proteinvaccinepræparater
Paoletti Recombinant avipox virus